Skip to main content
Equibles
NRXP logo

NRXP · NRX Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio

Track NRXP — free

Use NRXP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NRXP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.95 +0.08 (+2.79%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements.”
View the 10-Q filed Aug 14, 2026
Market Cap
$129.67M
Shares
43.30M
Volume · Oct 5 680.82K Avg daily vol (3M) 884.52K

NRX Pharmaceuticals, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for NRX Pharmaceuticals, Inc. (NRXP), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$1.62M '24 Q3 24-11-15 · $ −$5.51M '25 Q1 25-05-31 · $ −$17.58M '25 Q2 25-08-20 · $242,000 −$5.89M '25 Q3 25-11-17 · $983,000 $361,000 '25 Q4 26-03-24 · $1.07M −$1.43M '26 Q1 26-05-18 LATEST · $1.10M −$16.52M '26 Q2 26-08-17
Conference
Investor event
2026-09-09
NRX Pharmaceuticals, Inc. (NRXP) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-17
NRX Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript
Confident tone ALS program (GinEuro / GNK-301) SPARC-TMS trial with DARPA/military Preservative-free ketamine ANDA progress
Revenue
$1.10M
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-18
NRX Pharmaceuticals, Inc. (NRXP) Q1 2026 Earnings Call Transcript
Confident tone NRX-100 NDA and Regulatory Pathway NRX-101 and MIND-1 Trial Ketafree / Preservative-Free Ketamine Approval
Revenue
$1.07M
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
NRX Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript
Confident tone FDA engagement and regulatory designations NRX100 NDA and real-world evidence pathway Hope Therapeutics subsidiary and clinic network
Revenue
$983,000*
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-17
NRX Pharmaceuticals, Inc. (NRXP) Q3 2025 Earnings Call Transcript
Positive tone Regulatory milestones (NRX-100, NRX-101, KETAFREE) ONE-D protocol / TMS + DCS HOPE Therapeutics clinic network
Revenue
$242,000
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-20
NRX Pharmaceuticals, Inc. (NRXP) Q2 2025 Earnings Call Transcript
Confident tone NRX100 ketamine regulatory progress Hope Therapeutics clinic subsidiary FDA accelerated pathways and CNPV
Revenue
$
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-31
NRX Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript
Confident tone NRX-100 NDA and regulatory progress NRX-101 oral combination for suicidality HOPE Therapeutics clinic network
Revenue
$
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-17
NRX Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript
Confident tone HOPE Therapeutics Clinic Roll-Up NRX-101 Bipolar Depression NRX-100 Preservative-Free Ketamine NDA
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-15
NRX Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript
Confident tone NRX-100 NDA progress NRX-101 oral treatment for suicidal bipolar depression Suicidality public health mission
Revenue
$
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-15
NRX Pharmaceuticals, Inc. (NRXP) Q2 2024 Earnings Call Transcript
Confident tone NDA filings for NRX-100 and NRX-101 NRX-101 differentiation on safety (akathisia/suicidality) HOPE Therapeutics clinic roll-up
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-02
NRX Pharmaceuticals, Inc. (NRXP) Q1 2024 Earnings Call Transcript
Confident tone NRX-101 in bipolar depression / akathisia HTX-100 (IV ketamine) for suicidal depression Regulatory and FDA pathway
Diluted EPS
$-0.74
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
NRX Pharmaceuticals, Inc. (NRXP) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.70
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
NRX Pharmaceuticals, Inc. (NRXP) Q2 2023 Earnings Call Transcript
Diluted EPS
$-1.20
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
NRX Pharmaceuticals, Inc. (NRXP) Q1 2023 Earnings Call Transcript
Diluted EPS
$-1.66
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-31
NRX Pharmaceuticals, Inc. (NRXP) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
NRX Pharmaceuticals, Inc. (NRXP) Q3 2022 Earnings Call Transcript
Diluted EPS
$-1.40
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
NRX Pharmaceuticals, Inc. (NRXP) Q2 2022 Earnings Call Transcript
Diluted EPS
$-1.10
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
NRX Pharmaceuticals, Inc. (NRXP) Q1 2022 Earnings Call Transcript
Diluted EPS
$-2.10
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
NRX Pharmaceuticals, Inc. (NRXP) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-09-30
NRX Pharmaceuticals, Inc. (NRXP) Q3 2021 Earnings Call Transcript
Diluted EPS
$-7.20
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
NRX Pharmaceuticals, Inc. (NRXP) Q2 2021 Earnings Call Transcript
Diluted EPS
$-4.10
Audio Transcript Slides 8-K10-Q
Showing 1–22 of 22 webcasts
Key facts CIK 1719406 CUSIP 629444209 13F (30d) 1 filings 1 filers Visit website Investor relations